RxDoctor Payments Data

Alexandra Kitchener, APRN

Nurse Practitioner · Port Charlotte, FLNPI 1629616552

Payments from drug & device makers

$6,106in general payments, 2019–2025

Across 308 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$703
  • Novartis$561
  • Amgen$560
  • Merck$509
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$355
  • Esperion Therapeutics, Inc.$317
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$6,092100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,106 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$92,718
Medicare patients
452
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$132,999
Repatha SureclickEvolocumab44$48,336
EntrestoSacubitril/Valsartan35$44,408
JardianceEmpagliflozin17$23,586
NexlizetBempedoic Acid/Ezetimibe11$10,112
Rosuvastatin Calcium284$3,907
Isosorbide Mononitrate ErIsosorbide Mononitrate159$2,557
Potassium Chloride97$1,790
Ranolazine ErRanolazine16$1,731
Metoprolol Tartrate226$1,679
Atorvastatin Calcium90$916
Nebivolol Hcl11$859
Losartan Potassium75$806
Bumetanide16$781
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$275$132,999132 claims
NovartisEntresto$561$44,40835 claims
Boehringer IngelheimJardiance$283$23,58617 claims
Esperion Therapeutics, Inc.Nexlizet$317$10,11211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →